SER130AMI

Preclinical phase

Phase i

Phase ii a

Phase ii b

Phase iii

Approved

SER130 is a potent interleukin-4 (IL-4) agonist.

In patients suffering from an AMI, the blood supply to an area of the heart is acutely reduced or completely blocked, which immediately initiates an inflammatory process in the surrounding tissue. The consequence of the inflammation is damage of the heart muscle cells. This damage may create the background for arrhythmias and heart failure both in the acute phase and later when the condition has stabilized and become chronic.

Treatment of the patients with AMI is first  to give acutely administer pain killers such as morphine, supply oxygen, and diuretic treatment.

ECG measurements and cardiac imaging creates the background for treatment with percutaneous coronary intervention (PCI) and placement of a stent.

SER130 will be given as an intravenous bolus injection followed by an infusion as soon as the patient has arrived in hospital, often within a few hours after the heart attack.